Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Specificity, frequency, and phenotype of citrullinated-specific T cells vary with disease activity in rheumatoid arthritis
Cliff Rims, Hannah A. DeBerg, Sylvia E. Posso, Virginia S. Muir, Hannes Uchtenhagen, Anne M. Hocking, Heather Bukiri, Jeffrey Carlin, Bernard Ng, Peter S. Linsley, Eddie A. James, Jane H. Buckner
Cliff Rims, Hannah A. DeBerg, Sylvia E. Posso, Virginia S. Muir, Hannes Uchtenhagen, Anne M. Hocking, Heather Bukiri, Jeffrey Carlin, Bernard Ng, Peter S. Linsley, Eddie A. James, Jane H. Buckner
View: Text | PDF
Research Article Immunology

Specificity, frequency, and phenotype of citrullinated-specific T cells vary with disease activity in rheumatoid arthritis

  • Text
  • PDF
Abstract

In rheumatoid arthritis (RA), CD4+ T cells specific for citrullinated antigens (cit-antigens) are key drivers of disease, but knowledge about epitopes and phenotypes remains limited. We characterized the frequency and phenotype of cit-specific CD4+ T cells in peripheral blood using HLA class II tetramers combined with computational analysis of phenotypic clusters to simultaneously detect peptides derived from 5 cit-antigens (aggrecan, vimentin, fibrinogen, cartilage intermediate layer protein, and α-enolase) previously implicated in RA pathogenesis. In a cross-sectional cohort, cit-aggrecan–, cit-vimentin–, and cit-fibrinogen–specific T cells were more frequent in participants with RA than healthy volunteers, associated with active disease, and had Th1-like and stem-like lineages in RA. In a longitudinal cohort investigating response to therapy, the frequency of cit-aggrecan–, cit-vimentin–, and cit-fibrinogen–specific CD4+ T cells was significantly higher at baseline and further elevated in responders. Furthermore, the frequency of cit-specific Th1-like cells in responders decreased over time. In contrast, the frequency of Th1-like cells in non-responders increased over time. Collectively, these findings demonstrate that cit-specific CD4+ T cells are expanded in RA and target a broad number of antigens across a breadth of phenotypes. Furthermore, the predominant antigen specificities associate with disease activity and exhibit dynamic changes in phenotype that reflect response to therapy.

Authors

Cliff Rims, Hannah A. DeBerg, Sylvia E. Posso, Virginia S. Muir, Hannes Uchtenhagen, Anne M. Hocking, Heather Bukiri, Jeffrey Carlin, Bernard Ng, Peter S. Linsley, Eddie A. James, Jane H. Buckner

×

Figure 3

Among diverse cit-antigen–specific T cell phenotypes, distinct metaclusters are increased in active RA.

Options: View larger image (or click on image) Download as PowerPoint
Among diverse cit-antigen–specific T cell phenotypes, distinct metaclust...
(A) Stacked bar graph of non-naive phenotype frequencies of each cit-antigen– and influenza-specific CD4+ T cells for HC and RA participants, where prominent metaclusters (MCs) within each antigen were identified by first testing for unequal variance by comparing the group means of the absolute deviations from the median (ADM) to the overall mean ADM, then MCs exceeding an upper limit (α = 0.1) were boxed and tested for statistical significance by comparing to the unboxed MCs using samples with at least 8 parent events — influenza (n = 88), aggrecan (n = 55), VimFib (n = 47), CILP (n = 52), and α-enolase (n = 54) (Supplemental Table 4). (B) Total, influenza-specific, and cit-antigen–specific percentages of MC4 (EM CXCR3+) based on disease status. HC, closed circles; RA, open circles. Kruskal-Wallis test with multiple comparisons: aggrecan P = 0.0270 and CILP P = 0.0214. (C) Stacked bar graph of cit-RA CD4+ T cell phenotype distribution for those RA participants with high disease activity (wRAPID3 > 4.0) defined by aggrecan (n = 4) and VimFib (n = 6) dominance and participants near remission (wRAPID3 < 1.0) no dominance (n = 5); boxed are MC4 (EM CXCR3+) for each group. (D) Percentage MC4 (EM CXCR3+) of non-naive cell subset for individuals with high disease activity who are dominant for either aggrecan or VimFib compared with individuals in remission who have no dominant antigen specificity. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 by non-parametric Wilcoxon test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts